The IL-22 receptor, IL-22RA1, is known to be expressed on metabolic tissue, with the highest expression in the pancreas. We had previously discovered that exogenous IL-22 treatment is highly efficacious in metabolic disease [1]. By facilitating the secretion of high quality insulin, exogenous IL-22 treatment resulted in benefits including: complete restoration of glucose tolerance, suppression of fasting hyperinsulinemia/hyperproinsulinemia, and restoration of insulin sensitivity. However, the role of endogenous pancreatic IL-22RA1 signaling in maintaining metabolic homeostasis remained unknown. To understand the role of endogenous IL-22RA1 signaling in pancreatic β-cells, we generated tissue specific IL-22RA1 knockout mice lacking the receptor in pancreatic β-cells (IL-22RA1-/- Ins2Cre) and challenged them with a high fat diet. As the IL-22RA1-/-Ins2Cre mice aged, they had impaired glucose tolerance compared to littermate control animals, and this was exacerbated when the mice were challenged with a high fat diet. Our data demonstrates the importance of endogenous IL-22 in the pancreas as the ablation of pancreatic β-cell IL-22RA1 signaling resulted in reduced insulin biosynthesis in the 20-week-old animals. The liver is a major organ in the control of glucose homeostasis, and was examined in order to evaluate its role in the metabolic phenotype observed. IL-22RA1-/- Ins2Cre animals had decreased hepatic expression of the insulin-regulated lipogenic marker Srebp1-c, and the glucose transporter Glut-2. This was accompanied by increased hepatic expression of inflammatory cytokines (Tnfa, Il1b, Il10, Ccl2) and cellular stress (Nos2, Grp78). Taken together, our data indicates that IL-22RA1 signaling in pancreatic beta cells is hepatoprotective and plays an essential role in insulin-mediated glucose metabolism.